Pat McGeer

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Doctor
Patrick Lucey McGeer
OC OBC FRSC
Member of the British Columbia Legislative Assembly
for Vancouver-Point Grey
In office
December 17, 1962 – October 22, 1986
Serving with Robert Bonner and
Ralph Raymond Loffmark (1962-1966)
Garde Gardom (1966-1986)
Preceded by Buda Brown
Succeeded by Kim Campbell
Darlene Marzari
Leader of the
British Columbia Liberal Party
In office
October 1968 – May 22, 1972
Preceded by Ray Perrault
Succeeded by David Anderson
Personal details
Born Patrick Lucey McGeer
(1927-06-29) June 29, 1927 (age 90)
Vancouver, British Columbia
Nationality Canadian
Political party British Columbia Social Credit Party (1972-1986)
British Columbia Liberal Party (1962-1972)
Alma mater University of British Columbia
Princeton University
Occupation Neuroscientist

Patrick Lucey "Pat" McGeer, OC, OBC, FRSC (born June 29, 1927), is a Canadian physician, professor and medical researcher. He is regarded as a leading authority on the causes and prevention of Alzheimer's disease and is the principal author of the inflammatory hypothesis of the disease,[1] which holds that Alzheimer's is an inflammation of the cortex. Formerly, he was a Canadian basketball player who competed in the 1948 Summer Olympics, a politician who represented the constituency of Vancouver-Point Grey in the British Columbia legislature from 1962 to 1986, and a member of the British Columbia cabinet from 1976 to 1986. In 1995, he and his wife Edith were inducted as Officers of the Order of Canada. In 2002 they were jointly inducted as Fellows of the Royal Society of Canada, and in 2005 they were jointly inducted into the Order of British Columbia.

Aurin Biotech[edit]

In August 2012, McGeer and his wife Edith founded Aurin Biotech Inc., following indications that the Aurintricarboxylic acid (ATA) complex inhibit activation of the Complement system. Since activation of the complement system is implicated in a number of diseases (see Complement system#Role in Disease), these indications suggested that ATA could be an effective treatment for these diseases. Aurin[2] was founded to explore the efficacy of using ATA and related compounds in the treatment of these diseases. The particular focus is on diseases that are caused or exacerbated by aberrant complement activation. Low molecular weight components of the aurintricarboxylic acid complex have been shown to be non-toxic and orally effective.

References[edit]

External links[edit]